151 related articles for article (PubMed ID: 31545703)
1. Too Many Avoidable Suicides Occur Worldwide in Young Patients.
Rose K; Neubauer D; Grant-Kels JM
Rambam Maimonides Med J; 2019 Oct; 10(4):. PubMed ID: 31545703
[TBL] [Abstract][Full Text] [Related]
2. The Meanings of "Pediatric Drug Development".
Rose K; Grant-Kels JM
Ther Innov Regul Sci; 2019 Nov; 53(6):767-774. PubMed ID: 30526039
[TBL] [Abstract][Full Text] [Related]
3. Questionable Industry-Sponsored Postneonatal Pediatric Studies in Slovenia.
Rose K; Neubauer D; Grant-Kels JM
Curr Ther Res Clin Exp; 2019; 90():86-91. PubMed ID: 31388360
[TBL] [Abstract][Full Text] [Related]
4. The Challenges of Pediatric Drug Development.
Rose K
Curr Ther Res Clin Exp; 2019; 90():128-134. PubMed ID: 31388368
[TBL] [Abstract][Full Text] [Related]
5. Rational Use of Medicine in Children-The Conflict of Interests Story. A Review.
Rose K; Neubauer D; Grant-Kels JM
Rambam Maimonides Med J; 2019 Jul; 10(3):. PubMed ID: 31335307
[TBL] [Abstract][Full Text] [Related]
6. Neurology's vital role in preventing unnecessary and potentially harmful pediatric studies.
Rose K; Ettienne EB; Grant-Kels JM; Striano P; Neubauer D; Tanjinatus O
Expert Rev Neurother; 2022 Mar; 22(3):209-219. PubMed ID: 35213279
[TBL] [Abstract][Full Text] [Related]
7. Pediatric Melanoma and Drug Development.
Rose K; Grant-Kels JM
Children (Basel); 2018 Mar; 5(3):. PubMed ID: 29558389
[TBL] [Abstract][Full Text] [Related]
8. Do the European Medicines Agency Decisions Hurt Pediatric Melanoma Patients?
Rose K; Walson PD
Clin Ther; 2017 Feb; 39(2):253-265. PubMed ID: 28159363
[TBL] [Abstract][Full Text] [Related]
9. A New Ethical Challenge for Institutional Review Boards (IRBs)/Ethics Committees (ECs) in the Assessment of Pediatric Clinical Trials.
Rose K; Kummer H
Children (Basel); 2015 May; 2(2):198-210. PubMed ID: 27417359
[TBL] [Abstract][Full Text] [Related]
10. European Union pediatric legislation jeopardizes worldwide, timely future advances in the care of children with cancer.
Rose K
Clin Ther; 2014 Feb; 36(2):163-77. PubMed ID: 24529288
[TBL] [Abstract][Full Text] [Related]
11. Children with multiple sclerosis should not become therapeutic hostages.
Rose K; Müller T
Ther Adv Neurol Disord; 2016 Sep; 9(5):389-95. PubMed ID: 27582894
[TBL] [Abstract][Full Text] [Related]
12. The contributions of the European Medicines Agency and its pediatric committee to the fight against childhood leukemia.
Rose K; Walson PD
Risk Manag Healthc Policy; 2015; 8():185-205. PubMed ID: 26604845
[TBL] [Abstract][Full Text] [Related]
13. New Drugs for Rare Diseases in Children.
Rose K
Clin Ther; 2017 Feb; 39(2):246-252. PubMed ID: 28161117
[TBL] [Abstract][Full Text] [Related]
14. Pediatric Medicine Development: An Overview and Comparison of Regulatory Processes in the European Union and United States.
Penkov D; Tomasi P; Eichler I; Murphy D; Yao LP; Temeck J
Ther Innov Regul Sci; 2017 May; 51(3):360-371. PubMed ID: 28674673
[TBL] [Abstract][Full Text] [Related]
15. Mandatory requirements for pediatric drug development in the EU and the US for novel drugs-A comparative study.
Christiansen H; De Bruin ML; Hallgreen CE
Front Med (Lausanne); 2022; 9():1009432. PubMed ID: 36388912
[TBL] [Abstract][Full Text] [Related]
16. Similarities and differences in the oncology drug approval process between FDA and European Union with emphasis on in vitro companion diagnostics.
Senderowicz AM; Pfaff O
Clin Cancer Res; 2014 Mar; 20(6):1445-52. PubMed ID: 24634467
[TBL] [Abstract][Full Text] [Related]
17. Completion Rate and Reporting of Mandatory Pediatric Postmarketing Studies Under the US Pediatric Research Equity Act.
Hwang TJ; Orenstein L; Kesselheim AS; Bourgeois FT
JAMA Pediatr; 2019 Jan; 173(1):68-74. PubMed ID: 30452498
[TBL] [Abstract][Full Text] [Related]
18. Priority review drugs approved by the FDA and the EMA: time for international regulatory harmonization of pharmaceuticals?
Alqahtani S; Seoane-Vazquez E; Rodriguez-Monguio R; Eguale T
Pharmacoepidemiol Drug Saf; 2015 Jul; 24(7):709-15. PubMed ID: 26013294
[TBL] [Abstract][Full Text] [Related]
19. A Comparative Review of Waivers Granted in Pediatric Drug Development by FDA and EMA from 2007-2013.
Egger GF; Wharton GT; Malli S; Temeck J; Murphy MD; Tomasi P
Ther Innov Regul Sci; 2016 Sep; 50(5):639-647. PubMed ID: 27274951
[TBL] [Abstract][Full Text] [Related]
20. [Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan].
Pflieger M; Bertram D
Arch Pediatr; 2014 Oct; 21(10):1129-38. PubMed ID: 25175054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
